![[Next-Generation Sequencing Book]](https://www.bioinformatics.org/images/ack_banners/NGS-Book-1-728x90.png)
Featured prior sponsors:
Regeneron
St. Jude
Illumina BioSpace
Georgetown University
Northeastern University
Become a sponsor
Lastest news items (10)
| Submit | Archive | Subscribe |
-
An international consortium has announced that, powered by Google's AI tools, the Earth BioGenome Project is on schedule to sequence the genomes of all 1.85 million known eukaryotic species by 2028, a decade-long effort that has already reduced sequencing errors by up to 50 percent and is accelerating the creation of a complete genetic catalog of life on Earth.
Source: https://newatlas.com/biology/ai-sequencing-genomes-all-species-google-ebp/
Earth BioGenome Project: https://www.earthbiogenome.org
![[Photo]](https://www.bioinformatics.org/images/photo.php?photo_id=3)
-
December 12th, 2025 10:00 EST
https://www.bocsci.com/delivery-nanocarriers-to-desirable-vascular-destinations-fortuitous-tropism-vs-cognizant-targeting.html
Free registration
In this session, Dr. Vladimir Muzykantov will present an in-depth analysis of the current advances and challenges in drug targeting, biomaterials, nanomedicine, drug delivery systems (DDS), intracellular delivery, and biotherapeutics (Bios).HIGHLIGHTS
Biotherapeutics (Bios) as a new pharmacological class: Discussion of their catalytic precision, biological potency, and delivery challenges within systemic circulation.
Delivery challenges and bottlenecks: Exploration of nanoscale targeting requirements, intracellular addressing (cytosol vs nucleus), and barriers to effective biodistribution and clearance.
Cognizant vs. Fortuitous Targeting Approaches: Comparison of rational ligand-based targeting versus chance discoveries ("fortuitous homing"), including advantages, limitations, and potential synergies.
Mechanistic understanding through DDS design: How tracing, modeling, and controlled modification of nanocarriers advance rational design for vascular delivery.
Re-engineering Fortuitous Nanocarriers: Strategies to transform serendipitous findings into predictable and tunable delivery platforms through modulation of carrier configuration, size, shape, and biological context.
Translational impact – Vascular Nanomedicine: Case studies where endothelial-targeted antioxidants, antithrombotics, and anti-inflammatory agents outperform untargeted drugs in animal models of lung injury, ischemia-reperfusion, and sepsis.
![[Photo]](https://www.bioinformatics.org/images/photo.php?photo_id=24490)
-
James Dewey Watson (April 6, 1928 – November 6, 2025) was best known for the discovery that changed biology forever: the double-helix structure of DNA.
In 1953, working with Francis Crick and drawing on essential data from Rosalind Franklin and others, he showed how DNA is organized – a paired spiral whose sequence of bases carries the instructions for life. That discovery did more than answer a question; it created the foundation for entirely new fields of science.
Watson also played a central role in the next major transformation: integrating computer science with biology. When he became director of the Human Genome Project from 1990 to 1992, sequencing the complete human genome was widely considered impossible within a single lifetime. Watson argued for rapid, large-scale sequencing, immediate public release of all data, and global collaboration. Those decisions shaped the way genomic data are handled today and made modern bioinformatics possible.
He was an early and strong supporter of personalized medicine – the idea that knowledge of a person's full genome could guide medical care. In 2007-2008, at the age of 79-80, he became one of the first people in the world to have their entire genome sequenced and published, demonstrating his confidence in the future of genomic medicine.
Watson spent his career pushing biology toward a future in which genomic information is collected and then analyzed and applied using computers. Today's laboratories, filled with machines that process billions of DNA bases, owe as much to his vision as they do to the double helix he helped reveal. He did not simply discover the structure of DNA; he ensured that we would keep reading and using it.
![[Photo]](https://www.bioinformatics.org/images/photo.php?photo_id=5)
-
Researchers cultured 250+ gut bacteria and found 134 "hidden" phages that could be awakened. Most stayed silent in the lab until exposed to human gut cells or complex bacterial communities.
That means phage activity depends on both the microbiome and the human host. Some phages have even lost the genes needed to reactivate, becoming permanent passengers.
This study gives us a powerful resource of real, testable phage-host pairs and shows that phages are active players shaping our gut ecosystem.ARTICLE
Dahlman, Samuel, Tom O. Delmont, Alejandro Reyes, Anna L. Mallott, and Emily B. Hollister, et al. "Isolation, Engineering and Ecology of Temperate Phages from the Human Gut." Nature 638 (2025): 145-152. https://doi.org/10.1038/s41586-025-09614-7.
-
A large UK study of breast cancer patients has found that sequencing the entire genome of a tumor can reveal important information about the aggressiveness of the disease and which treatments are most likely to work. By linking whole-genome data from thousands of tumors to long-term survival records, researchers identified specific DNA changes tied to prognosis and uncovered therapeutic targets that standard tests routinely miss, potentially allowing doctors to someday choose more effective, personalized therapies while sparing patients from treatments that offer little benefit. ARTICLE
Turnbull, Clare, Helen Davies, Peter Van Loo, Serena Nik-Zainal, and colleagues. "Clinical Potential of Whole-Genome Data Linked to Mortality Statistics in Patients with Breast Cancer in the UK: A Retrospective Analysis." The Lancet Oncology (2025). https://doi.org/10.1016/S1470-2045(25)00400-0
-
Researchers have created a new biological-age clock called gtAge that predicts aging more accurately than most existing methods. It works by analyzing two features measurable in a regular blood sample – the sugar patterns attached to antibodies (IgG glycosylation) and gene-activity levels in white blood cells. The team used deep reinforcement learning, an advanced form of artificial intelligence, to combine these data. They hope gtAge may eventually help doctors check whether a patient's diet, medication, or lifestyle changes are genuinely slowing aging and cutting the risk of age-related diseases. ARTICLE
Xia, Yao, Syed Mohammed Shamsul Islam, Xingang Li, Abdul Baten, Xuerui Tan, and Wei Wang. "Deep Reinforcement Learning – Driven Multi-Omics Integration for Constructing gtAge: A Novel Aging Clock from IgG N-glycome and Blood Transcriptome." Engineering (2025). https://doi.org/10.1016/j.eng.2025.08.016.
-
A team of researchers has built a new tool called MetaGraph, designed to let scientists search across some of the largest collections of DNA and RNA sequences ever assembled (databases that together hold more than a quadrillion bases). With MetaGraph, queries that once took weeks, or were simply impossible, can now return results in minutes, even when the search spans global repositories such as the Sequence Read Archive. This speed and reach now make it possible to detect subtle relationships between particular genes, microbial species, and human diseases that were previously hidden inside vast amounts of raw, unanalyzed sequencing data. ARTICLE
Karasikov, Mikhail, Harun Mustafa, Daniel Danciu, Oleksandr Kulkov, Marc Zimmermann, Christopher Barber, Gunnar Rätsch, and André Kahles. "Efficient and Accurate Search in Petabase-Scale Sequence Repositories." Nature (October 8, 2025). https://doi.org/10.1038/s41586-025-09603-w.
-
Frontiers, an open-science publisher, has launched FAIR² Data Management, an AI-powered service designed to address the fact that approximately 90% of scientific data never gets reused to drive new discoveries. The platform automates data curation, compliance checking, and formatting – tasks that previously took months – to make research datasets properly preserved, citable, and reusable by both humans and AI systems. Out of every 100 datasets created, about 80 remain in labs and only one typically leads to new findings, a bottleneck that delays advances in fields like cancer treatment and climate research. The service has completed pilot projects spanning COVID variants, brain injury research, climate indicators, and biodiversity, with researchers noting that it could accelerate scientific progress while ensuring data creators receive proper credit for their work.
Source: https://www.frontiersin.org/news/2025/10/13/90-of-science-is-lost-frontiers-revolutionary-ai-powered-service-transforms
-
A new method called SDR-seq – short for single-cell DNA-RNA sequencing – enables researchers to measure DNA mutations and gene activity within the same cell, offering a direct view of how genetic variation shapes cell function. The approach improves on previous multi-omic techniques, which often suffered from data loss and could not reliably connect genotype to transcriptomic effects at single-cell resolution. By reducing allelic dropout and scaling to hundreds of genomic targets, SDR-seq provides more accurate and comprehensive insights, demonstrating its effectiveness in both laboratory models and primary tumour samples. ARTICLE
Lindenhofer, Dominik, Christian E. Saliba, René Schmutz, et al. "Functional Phenotyping of Genomic Variants Using Joint Multiomic Single-Cell DNA-RNA Sequencing." Nature Methods (2025). https://doi.org/10.1038/s41592-025-02805-0.
-
A large-scale genomic study of more than 218,000 participants in Geisinger's MyCode Community Health Initiative has revealed that rare genetic disorders (RGDs) may be more common and less clinically recognised than previously thought. Researchers found that 2.5% of participants carried high-confidence pathogenic variants linked to RGDs, yet only about one in five of those who were positive had corresponding clinical diagnoses. The findings suggest that genomic-first approaches could identify many undiagnosed cases, refine estimates of disease penetrance, and improve early diagnosis and management of RGDs. ARTICLE
Torene, Rebecca I., et al. "A Scalable Approach for Genomic-First Rare Disorder Detection in a Healthcare-Based Population." The American Journal of Human Genetics, published online October 6, 2025. https://doi.org/10.1016/j.ajhg.2025.09.010. [not open-access]
| Submit | Archive | Subscribe |